MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
two doctors, a man and a woman, examine an MRI image of the brain

FDA Decision On Tolebrutinib

MStranslate
January 12, 2026
Clinical Trials
A pair of hands around a crystal ball that has the year 2026 written inside it.

Multiple Sclerosis Research In 2026

MStranslate
January 5, 2026
Progressive MS, Remyelination, Treatments
ECTRIMS Congress 2025

Revisiting ECTRIMS Congress 2025

MStranslate
November 18, 2025
ECTRIMS, Podcasts, Research
The ECTRIMS Podcast

UPDATED: The ECTRIMS Podcast – Episode Library

MStranslate
September 10, 2025
ECTRIMS, Podcasts, Research
Patient Community Day

Patient Community Day at ECTRIMS 2025

MStranslate
July 22, 2025
ECTRIMS, Events, Research
BTK inhibitors

BTK Inhibitors in the Treatment of MS

MStranslate
December 12, 2023
Clinical Trials, Research, Treatments
What is Bruton’s Tyrosine Kinase (BTK)? Bruton’s Tyrosine Kinase, or BTK, is an enzyme in the body that plays a role in the activity of B cells.  B cells, which are important cells in the immune system,...
MS Milan 2023 Podcast

The MS Milan 2023 Podcast: Daily Episodes

MStranslate
November 16, 2023
Conferences, ECTRIMS, Podcasts
Following the success of The ECTRIMS Podcast 2022 and its subsequent episodes throughout 2023, the European Committee for Treatment and Research in Multiple Sclerosis organisation once again invited our...
MS Milan 2023

MS Milan 2023: Daily Research Summary Videos

MStranslate
October 19, 2023
ACTRIMS, ECTRIMS, Research
1 Comment
MS Milan 2023 was the 9th Joint ECTRIMS-ACTRIMS Meeting, coordinated by the European Congress for the Treatment and Research Into Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and...
An image of the human brain with nerve cells firing and then a zoomed in image of a nerve with impulses going off in various directions

Clemastine Repairs Damage In Multiple Sclerosis

MStranslate
July 4, 2023
Clinical Trials, Neuroimaging, Remyelination
Research Summary: MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial Remyelination or myelin repair is the next big step in the treatment of multiple sclerosis. ...
neural stem cell

Neural Stem Cell Transplantation for Progressive MS

MStranslate
March 28, 2023
Research, Stem Cells, Treatments
1 Comment
Research Summary: Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study The treatment of progressive multiple sclerosis remains an unmet need. ...
COVID Infection multiple sclerosis

COVID-19 Infection and Multiple Sclerosis

MStranslate
March 14, 2023
COVID-19, Infection, Research
MStranslate co-founder, Brett Drummond, explores and explains a recently published research paper that has identified COVID-19 infection as a potential trigger for multiple sclerosis. While the outcomes of...
remyelination research

Remyelination in Multiple Sclerosis: New Insights

MStranslate
January 16, 2023
Dr Travis Stiles, ECTRIMS, Remyelination, Research
1 Comment
Late in 2022, we published two new videos that provided insights on the topic of remyelination research in multiple sclerosis (MS). The first video was recorded at the European Committee for Treatment and...
multiple sclerosis nurses

The Value of Specialist Multiple Sclerosis Nurses

MStranslate
November 29, 2022
ECTRIMS, Research, Videos
At the recent European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, Belinda Bardsley (Austin Health, Australia) presented on a research study that assessed the impact...
ECTRIMS 2022

ECTRIMS 2022: Daily Podcasts & Summary Videos

MStranslate
November 21, 2022
Conferences, ECTRIMS, Research
The 38th meeting of the European Congress for the Treatment and Research Into Multiple Sclerosis (ECTRIMS) took place in Amsterdam, The Netherlands, between the 26th and 28th of October, 2022. The ECTRIMS...
Facebook Live

Facebook Live: Special Guest Announcement

MStranslate
September 28, 2022
Dr Travis Stiles, Q&A, Research, Videos
On September 25, 2022, our co-founder and chief science communicator, Brett Drummond, took to Facebook Live with a very special guest, Dr Travis Stiles (CEO, Novoron Bioscience). Many who follow MStranslate...
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.